Cimzia (Certolizumab Pegol)
What is a Generic Drug?
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Coming Soon – Save up to 85%
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Prescription Required
-
Product Details
Description
Cimzia (certolizumab pegol) is an injectable medication used to treat adults with the following conditions:
- Crohn’s disease
- Rheumatoid arthritis
- Active psoriatic arthritis
- Ankylosing spondylitis
- Non-radiographic axial ankylosing spondylarthritis with inflammatory signs
- Moderate-to-severe plaque psoriasis who are eligible to receive systemic therapy or phototherapy
Cimzia is available in either a single-dose vial containing 200 mg lyophilized powder or a single-dose prefilled syringe containing 200 mg/mL of solution.
Fact Table
Formula
C2260H3528N618O673S16 (Fab' fragment, without PEG)
License
US FDA, EMA
Bioavailability
~80% (Subcutaneous)
Legal status
Prescription only (Rx)
Chemical Name
Certolizumab Pegol
Elimination half-life
~14 days
Dosage (Strength)
200 mg/mL solution in pre-filled syringe or pen
Pregnancy
Consult a doctor
Brands
Cimzia
Protein binding
~95% (Fab' fragment)
PubChem CID
9931913
MedlinePlus
a608007
ChEBI
CHEBI:63737
ATC code
L04AB05
DrugBank
DB08905
KEGG
D03621
Routes of administration
Subcutaneous
Directions
Use Cimzia injection exactly as prescribed by your doctor. Your doctor will determine an appropriate treatment regimen for you based on the condition being treated. You or your caregiver should receive training on how to properly store, prepare, administer, and discard Cimzia.
Cimzia is for subcutaneous (underneath the skin) injection in the thigh or abdomen. Injection sites should be rotated with each injection.
Carefully read the medication guide that comes with your prescription for product use information. Tell your doctor or pharmacist about any questions or concerns you may have about the medication.
Needles and syringes should never be reused or shared with other people.
Ingredients
The active ingredient in Cimzia is certolizumab pegol.
Inactive ingredients in the lyophilized powder include lactic acid, polysorbate, and sucrose. Water for Injection is also used for mixing.
Inactive ingredients in the prefilled syringe include sodium acetate, sodium chloride, and Water for Injection.
Contraindications
Patients with a serious allergy to certolizumab pegol or to any of the other ingredients in Cimzia should not receive it.
Cautions
- Cimzia contains the following FDA Boxed Warning:
- The risk of serious infections that result in hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections caused by other opportunistic pathogens is increased.
- If a patient develops a serious infection or sepsis, Cimzia should be stopped.
- A test for latent TB should be performed. Treatment for TB should be initiated before starting Cimzia if the test is positive.
- All patients should be monitored for active TB during treatment, even if their first latent TB test is negative.
- Children and adolescents who were treated with TNF blockers like Cimzia have developed potentially fatal lymphoma and other malignancies; therefore, Cimzia is not approved for use in pediatric patients.
- Before you begin treatment with Cimzia, inform your doctor of:
- All the prescription and over-the-counter medications you take
- Your allergies
- Your current health problems and past medical history
- Your pregnancy or breastfeeding status
- Cimzia is associated with the following warnings and precautions:
- Serious infections
- Malignancies, or cancers
- Heart failure
- Hypersensitivity reactions
- Hepatitis B virus reactivation
- Neurological reactions
- Bleeding problems
- Lupus-like syndrome
- Do not use Cimzia with Anakinra, abatacept, rituximab, or natalizumab, as the risk of serious infections is increased.
- Live vaccines should not be administered to patients receiving treatment with Cimzia.
Side Effects
Upper respiratory tract infection, rash, and urinary tract infection are common Cimzia side effects; however, other side effects may also occur. Immediately inform your doctor of any side effects that bother you or won’t go away.
You can buy Cimzia right here!
Reference
Cimzia. Smyrna, GA: UCB, Inc.; 2022.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.Product Code : 11374
-
Product Reviews
